Glycosylation News and Research

RSS

Certain antibodies may cause the dangerous part of COVID-19 disease

A new study out of the Netherlands and published on the preprint server bioRxiv* in July 2020 discusses the commonly observed phenomenon of COVID-19 progression at 1-2 weeks from the onset of the earliest symptoms. This is ascribed to the overactivation of the inflammatory signaling cascade triggered by a hyperactive adaptive immune reaction, commonly called the cytokine storm.

15 Jul 2020

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020

Spike proteins of SARS-CoV-2 covered by mobile glycans that shield its surface

A new study of the structural dynamics of the SARS-CoV-2 spike protein published in the preprint server bioRxiv in July 2020 reports on the epitopes that could be possible immune targets for the development of vaccines.

7 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

Research shows how a protein's small change leads to big trouble for cells

In molecular biology, chaperones are a class of proteins that help regulate how other proteins fold. Folding is an important step in the manufacturing process for proteins. When they don't fold the way they're supposed to, it can lead to the development of diseases such as cancer.

30 Jun 2020

A glycan analysis of SARS-CoV-2 ACE2 complex

Researchers in the U.S. have produced molecular dynamic simulations of the Spike protein found on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

29 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Glycans "lock and load" the SARS-CoV-2 spike protein for infection

A new study by scientists from the University of California San Diego, USA and Maynooth University, Ireland and published on the preprint server bioRxiv* in June 2020 reports preliminary results showing that the spike protein of the SARS-CoV-2, as well as its glycan coat, has “hitherto unseen functional and structural” properties. These may be useful in designing novel therapeutics to target this molecule.

14 Jun 2020

Researchers question the mechanism of retinitis pigmentosa

Researchers who made a knock-in mouse-model of the genetic disorder retinitis pigmentosa 59, or RP59, expected to see retinal degeneration and retinal thinning. As reported in the journal Cells, they surprisingly found none, calling into question the commonly accepted -- though never proved -- mechanism for RP59.

12 Jun 2020

Unique mutations could weaken Indian SARS-CoV-2 strain

A new study published on the preprint server bioRxiv in June 2020 suggests that the presence of unique mutations in the viral strains circulating in India has led to their attenuation.

9 Jun 2020

New strategy may facilitate development of multi-epitope peptide vaccine against SARS-CoV-2

By combining T and B lymphocyte analysis with manufacturability heuristic, researchers from the US and Germany proposed a set of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine peptides to use in subsequent animal studies and clinical trials. Their paper is currently available on the bioRxiv preprint server.

7 Jun 2020

New test identifies CAD-affected children who may benefit from uridine

Scientists at Sanford Burnham Prebys Medical Discovery Institute and the Centro de Biología Molecular Severo Ochoa in Spain have created a test that determines which children with CAD deficiency-; a rare metabolic disease-; are likely to benefit from receiving uridine, a nutritional supplement that has dramatically improved the lives of other children with the condition.

3 Jun 2020

Examining the envelope protein of SARS-CoV-2

A new study by researchers at the University of Valencia and published on the preprint online server bioRxiv in May 2020 reports the topology of the envelope protein of the virus, which could contribute to a better understanding of how the virus interacts with other cell components and hopefully help to fight the disease better.

28 May 2020

Airway and Celonic collaborate to produce AT-100 as therapeutic candidate against COVID-19

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, and Celonic Group, a premium biopharmaceutical CDMO specialized in the development and production of Advance Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed biotherapeutics, today announced a collaboration to produce the novel human recombinant protein AT-100 (rhSP-D) as a therapeutic candidate against COVID-19.

21 May 2020

New and unexplored angle in the binding of SARS-CoV-2 to host cells

Researchers in the Netherlands, Cuba, and Italy have made important discoveries about the carbohydrate-mediated binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to host cell lectin receptors and host lung microbiota.

17 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

Hydroxychloroquine shown to slow recovery for COVID-19 patients

As researchers try to piece together a therapeutic strategy against the ongoing COVID-19 pandemic, a recent retrospective study from Cleveland Clinic Abu Dhabi, assessed the Hydroxychloroquine's efficacy in increasing SARS-CoV-2 viral clearance, finding that it appeared to significantly slow viral clearance in mild to moderately ill COVID-19 patients.

5 May 2020

How toxic are chloroquine and hydroxychloroquine to cells?

The spread of the pandemic disease COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has now reached almost every country of the world, with over 3.11 million cases and over 217,000 deaths as of April 29, 2020.

29 Apr 2020

Research on SARS-CoV-2 spike protein may lead to new vaccines and treatments

The virus that causes COVID-19 is studded on its exterior with "spike proteins," a key component in its ability to infect human cells. Two University of Georgia researchers, Rob Woods and Parastoo Azadi, are investigating the proteins and sugars on the surface of the virus with the goal of finding information that could lead to vaccines and therapeutics.

28 Apr 2020